Бривекимиг

Prop. INN (наименование, предложенное ВОЗ)

2834733-45-6

immunoglobulin IG single chain of 5 VH (VH-VH-VH'-VH''-VH') monomer, anti-[Homo sapiens TNFSF4 (TNF superfamily member 4, tumor necrosis factor superfamily member 4, OX40 ligand, OX40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252)], anti-[Homo sapiens TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], monoclonal antibody VH-VH-VH'-VH''-VH', trispecific, pentavalent;
IG single chain VH-VH-VH'-VH''-VH' (1-630) [VH anti-TNFSF4 Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (89.8%) -(IGHD) -IGHJ7*01 (92.3%) K120>Q (116)/Homo sapiens IGHV3-23*04 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.8.16] (26-34.52-59.98-113)) (1-124) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (125-133) -VH anti-TNFSF4 Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (88.9%) -(IGHD) -IGHJ7*01 (92.3%) K120>Q (249)/Homo sapiens IGHV3-23*04 (83.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.8.16] (159-167.185-192.231-246)) (134-257) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (258-266) -VH anti-TNF (Homo sapiens IGHV3-20*04 (87.8%) -(IGHD) -IGHJ1*01 (91.9%) W118>R (371), CDR-IMGT [8.8.8] (292-299.317-324.363-370)) (267-381) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (382-390) -VH anti-ALB (Homo sapiens IGHV3-23*04 (88.5%) -(IGHD) -IGHJ1*01 (81.8%) W118>S (495), G119>S (496), CDR-IMGT [8.8.8] (416-423.441-448.487-494)) (391-505) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (506-514) -VH anti-TNF (Homo sapiens IGHV3-20*04 (87.8%) -(IGHD) -IGHJ1*01 (90.0%) W118>R (619), CDR-IMGT [8.8.18] (540-547.565-572.611-618)) (515-630)], produced in the yeast Pichia pastoris (Komagataella phaffii), non-glycosylated

Поделиться этой страницей